Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Streptococcus Pyogenes Infections - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Streptococcus Pyogenes Infections - Pipeline Review, H1 2015', provides an overview of the Streptococcus Pyogenes Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Streptococcus Pyogenes Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pyogenes Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus Pyogenes Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Streptococcus Pyogenes Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Streptococcus Pyogenes Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Streptococcus Pyogenes Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Streptococcus Pyogenes Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Streptococcus Pyogenes Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Streptococcus Pyogenes Infections Overview 6 Therapeutics Development 7 Pipeline Products for Streptococcus Pyogenes Infections - Overview 7 Pipeline Products for Streptococcus Pyogenes Infections - Comparative Analysis 8 Streptococcus Pyogenes Infections - Therapeutics under Development by Companies 9 Streptococcus Pyogenes Infections - Therapeutics under Investigation by Universities/Institutes 10 Streptococcus Pyogenes Infections - Pipeline Products Glance 11 Early Stage Products 11 Streptococcus Pyogenes Infections - Products under Development by Companies 12 Streptococcus Pyogenes Infections - Products under Investigation by Universities/Institutes 13 Streptococcus Pyogenes Infections - Companies Involved in Therapeutics Development 14 Absynth Biologics Limited 14 GlycoVaxyn AG 15 Helix BioMedix, Inc. 16 Novartis AG 17 Sumitomo Dainippon Pharma Co., Ltd. 18 Wellstat Vaccines, LLC 19 Streptococcus Pyogenes Infections - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 26 Drug Profiles 28 HB-1345 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 SM-295291 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 SM-369926 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 streptococcus [serotype A] vaccine - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 streptococcus [serotype A] vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 streptococcus pyogenes vaccine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 streptococcus pyogenes vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 streptococcus pyogenes vaccine (30-valent) - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 streptococcus vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Streptococcus Pyogenes Infections - Recent Pipeline Updates 39 Streptococcus Pyogenes Infections - Dormant Projects 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables Number of Products under Development for Streptococcus Pyogenes Infections, H1 2015 7 Number of Products under Development for Streptococcus Pyogenes Infections - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Products under Investigation by Universities/Institutes, H1 2015 13 Streptococcus Pyogenes Infections - Pipeline by Absynth Biologics Limited, H1 2015 14 Streptococcus Pyogenes Infections - Pipeline by GlycoVaxyn AG, H1 2015 15 Streptococcus Pyogenes Infections - Pipeline by Helix BioMedix, Inc., H1 2015 16 Streptococcus Pyogenes Infections - Pipeline by Novartis AG, H1 2015 17 Streptococcus Pyogenes Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 18 Streptococcus Pyogenes Infections - Pipeline by Wellstat Vaccines, LLC, H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 25 Number of Products by Stage and Molecule Type, H1 2015 27 Streptococcus Pyogenes Infections Therapeutics - Recent Pipeline Updates, H1 2015 39 Streptococcus Pyogenes Infections - Dormant Projects, H1 2015 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.